ERBB2 and breast carcinoma: Anti-HER2 monoclonal antibodies (mAbs)—trastuzumab, pertuzumab- have largely improved HER2+ BC patients’ prognosis by suppressing breast cancer cells (BCC) proliferation and enhancing cellular apoptosis2.